Last updated: March 7, 2026
What are the key facts of the case?
Cephalon Inc. filed a patent infringement lawsuit against Actavis Group in the District of Delaware in 2009. The core dispute involves patents related to Cephalon's brain cancer treatment, Provigil (modafinil). Cephalon accused Actavis of infringing its patents through the marketing and sale of generic versions of Provigil.
The patents at issue included U.S. Patent Nos. 6,630,507 and 7,339,698, covering methods of manufacturing and formulations of modafinil. Cephalon obtained exclusivity through these patents to prevent generic competition.
Actavis challenged the patents' validity and alleged non-infringement. The case was part of a broader wave of patent litigation involving drug patent holders defending market exclusivity.
What are the procedural milestones?
- 2009: Complaint filed by Cephalon.
- 2010: The U.S. District Court granted a preliminary injunction against Actavis, preventing sales of generic Provigil until patent issues were resolved.
- 2012: Court issued a final ruling finding the patents valid and infringed by Actavis.
- 2013: The Federal Circuit affirmed the district court’s decision.
- 2014: Settlement between Cephalon and Actavis; generic versions entered the market under licensing arrangements.
What were the court’s primary legal findings?
Patent Validity
The court upheld the validity of Cephalon’s patents, citing inventive aspects in the manufacturing process and sustained chemical stability of modafinil formulations.
Infringement
The court determined that Actavis’s generic product infringed Cephalon’s method and formulation patents. The claims were specific to the manufacturing process and the unique crystalline form of modafinil protected by the patents.
Non-Obviousness
The court found that the patent claims were not obvious combinations of existing knowledge, supporting the patents' enforceability.
Damages and Injunctions
Cephalon was awarded injunctive relief and damages for infringement. The damages reflected lost profits and royalties for patentholders.
What was the outcome?
This case reinforced patent protections for Cephalon and delayed generic entry until the patents were challenged and ultimately upheld. The eventual settlement allowed Actavis to produce generic Provigil under licensing terms, ending litigation but maintaining patent royalties.
How does this case compare with similar litigations?
- Similar patent battles in the pharmaceutical sector often involve lifelong patent protections and complex validity challenges.
- The case’s focus on method-of-manufacturing patents reflects a common strategy to extend market exclusivity beyond the initial compound patents.
- Federal Circuit’s affirmation of patent validity aligns with the judiciary’s trend of favoring patent enforceability for innovations in chemical and pharmaceutical processes.
Critical issues raised
Patent Scope and Patentability
The case underscores the importance of claims drafting, particularly for process patents, to demonstrate non-obviousness and inventive step.
Patent Litigation Strategy
Cephalon’s aggressive defense secured market exclusivity. Actavis’s challenge illustrates typical efforts to circumvent patents via validity arguments and design-arounds.
Settlement Dynamics
Licensing agreements emerged as a resolution mechanism, balancing patent rights and market competition.
Implications for industry stakeholders
- Patent inspectors should scrutinize process claims for inventive features.
- R&D strategies must consider patent life cycles and potential validity challenges.
- Generic manufacturers might pursue validity and non-infringement defenses early to delay patent enforcement.
Key Takeaways
- The dispute centered on method patents protecting Cephalon’s formulation of Provigil, leading to a successful infringement case.
- The Court upheld the patents’ validity, emphasizing non-obviousness in chemical process claims.
- Judicial support for patent enforceability impacts strategies around formulation innovations and process patents.
- Resolutions often include licensing agreements rather than litigation victory alone.
- Patent litigation remains a primary tool for brand-name drug holders to defend market exclusivity.
FAQs
1. How did the court determine patent validity in this case?
The court found the patents non-obvious based on the inventive manufacturing steps and chemical stability, supported by expert testimony and prior art analysis.
2. What role did process patents play in Cephalon’s legal strategy?
Process patents extended market exclusivity beyond compound patents and protected unique manufacturing techniques.
3. What was the significance of the Federal Circuit’s decision?
It affirmed the district court’s validity and infringement findings, reinforcing the strength of Cephalon’s patent rights.
4. How did the settlement impact the market?
The settlement allowed Actavis to enter the market with generic Provigil under licensing conditions, balancing patent rights and market competition.
5. What lessons can generic manufacturers learn from this case?
Challenging patent validity through comprehensive prior art searches and validity arguments can delay generic entry.
References
- U.S. District Court for the District of Delaware. (2012). Cephalon Inc. v. Actavis Group. Case No. 1:09-cv-00940. Retrieved from PACER.
- Federal Circuit Court of Appeals. (2013). Cephalon Inc. v. Actavis Group, No. 13-1124. Retrieved from www.cafc.uscourts.gov.
- U.S. Patent No. 6,630,507.
- U.S. Patent No. 7,339,698.
